Literature DB >> 33159421

Class IA PI3Ks regulate subcellular and functional dynamics of IDO1.

Alberta Iacono1, Andrea Pompa2,3, Francesca De Marchis3, Eleonora Panfili1, Francesco A Greco4, Alice Coletti4, Ciriana Orabona1, Claudia Volpi1, Maria L Belladonna1, Giada Mondanelli, Elisa Albini1,4, Carmine Vacca1, Marco Gargaro1, Francesca Fallarino1, Roberta Bianchi1, Carine De Marcos Lousa5,6, Emilia Mc Mazza7, Silvio Bicciato8, Elisa Proietti1, Francesca Milano9, Maria P Martelli9, Ioana M Iamandii1, Mariona Graupera Garcia-Mila10, Judith Llena Sopena10, Phillip Hawkins11, Sabine Suire11, Klaus Okkenhaug12, Anne-Katrien Stark12, Fabio Grassi13, Michele Bellucci3, Paolo Puccetti1, Laura Santambrogio14, Antonio Macchiarulo4, Ursula Grohmann1,15, Maria T Pallotta1.   

Abstract

Knowledge of a protein's spatial dynamics at the subcellular level is key to understanding its function(s), interactions, and associated intracellular events. Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytosolic enzyme that controls immune responses via tryptophan metabolism, mainly through its enzymic activity. When phosphorylated, however, IDO1 acts as a signaling molecule in plasmacytoid dendritic cells (pDCs), thus activating genomic effects, ultimately leading to long-lasting immunosuppression. Whether the two activities-namely, the catalytic and signaling functions-are spatially segregated has been unclear. We found that, under conditions favoring signaling rather than catabolic events, IDO1 shifts from the cytosol to early endosomes. The event requires interaction with class IA phosphoinositide 3-kinases (PI3Ks), which become activated, resulting in full expression of the immunoregulatory phenotype in vivo in pDCs as resulting from IDO1-dependent signaling events. Thus, IDO1's spatial dynamics meet the needs for short-acting as well as durable mechanisms of immune suppression, both under acute and chronic inflammatory conditions. These data expand the theoretical basis for an IDO1-centered therapy in inflammation and autoimmunity.
© 2020 The Authors.

Entities:  

Keywords:  dendritic cells; early endosomes; indoleamine 2,3-dioxygenase 1 (IDO1); phosphoinositide 3-kinase (PI3K); tryptophan metabolism

Mesh:

Substances:

Year:  2020        PMID: 33159421      PMCID: PMC7726814          DOI: 10.15252/embr.201949756

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   9.071


  65 in total

Review 1.  PI3K in lymphocyte development, differentiation and activation.

Authors:  Klaus Okkenhaug; Bart Vanhaesebroeck
Journal:  Nat Rev Immunol       Date:  2003-04       Impact factor: 53.106

2.  Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1.

Authors:  E Albini; A Coletti; F Greco; M T Pallotta; G Mondanelli; M Gargaro; M L Belladonna; C Volpi; R Bianchi; U Grohmann; A Macchiarulo; C Orabona
Journal:  Biochem Pharmacol       Date:  2018-11-01       Impact factor: 5.858

Review 3.  Endosomes: a legitimate platform for the signaling train.

Authors:  Jane E Murphy; Benjamin E Padilla; Burcu Hasdemir; Graeme S Cottrell; Nigel W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

Review 4.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

5.  Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate.

Authors:  S R Thomas; H Salahifar; R Mashima; N H Hunt; D R Richardson; R Stocker
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

6.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

7.  A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.

Authors:  Stephen Jamieson; Jack U Flanagan; Sharada Kolekar; Christina Buchanan; Jackie D Kendall; Woo-Jeong Lee; Gordon W Rewcastle; William A Denny; Ripudaman Singh; James Dickson; Bruce C Baguley; Peter R Shepherd
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

8.  A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells.

Authors:  Giada Mondanelli; Roberta Bianchi; Maria Teresa Pallotta; Ciriana Orabona; Elisa Albini; Alberta Iacono; Maria Laura Belladonna; Carmine Vacca; Francesca Fallarino; Antonio Macchiarulo; Stefano Ugel; Vincenzo Bronte; Federica Gevi; Lello Zolla; Auke Verhaar; Maikel Peppelenbosch; Emilia Maria Cristina Mazza; Silvio Bicciato; Yasmina Laouar; Laura Santambrogio; Paolo Puccetti; Claudia Volpi; Ursula Grohmann
Journal:  Immunity       Date:  2017-02-14       Impact factor: 31.745

9.  Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease.

Authors:  Giada Mondanelli; Alberta Iacono; Massimo Allegrucci; Paolo Puccetti; Ursula Grohmann
Journal:  Front Immunol       Date:  2019-07-09       Impact factor: 7.561

10.  Class IA PI3Ks regulate subcellular and functional dynamics of IDO1.

Authors:  Alberta Iacono; Andrea Pompa; Francesca De Marchis; Eleonora Panfili; Francesco A Greco; Alice Coletti; Ciriana Orabona; Claudia Volpi; Maria L Belladonna; Giada Mondanelli; Elisa Albini; Carmine Vacca; Marco Gargaro; Francesca Fallarino; Roberta Bianchi; Carine De Marcos Lousa; Emilia Mc Mazza; Silvio Bicciato; Elisa Proietti; Francesca Milano; Maria P Martelli; Ioana M Iamandii; Mariona Graupera Garcia-Mila; Judith Llena Sopena; Phillip Hawkins; Sabine Suire; Klaus Okkenhaug; Anne-Katrien Stark; Fabio Grassi; Michele Bellucci; Paolo Puccetti; Laura Santambrogio; Antonio Macchiarulo; Ursula Grohmann; Maria T Pallotta
Journal:  EMBO Rep       Date:  2020-11-07       Impact factor: 9.071

View more
  10 in total

Review 1.  Reducing PDK1/Akt Activity: An Effective Therapeutic Target in the Treatment of Alzheimer's Disease.

Authors:  Shaobin Yang; Yaqin Du; Xiaoqian Zhao; Chendong Wu; Peng Yu
Journal:  Cells       Date:  2022-05-24       Impact factor: 7.666

Review 2.  Moonlighting Proteins Are Important Players in Cancer Immunology.

Authors:  Annalisa Adamo; Cristina Frusteri; Maria Teresa Pallotta; Tracey Pirali; Silvia Sartoris; Stefano Ugel
Journal:  Front Immunol       Date:  2021-01-18       Impact factor: 7.561

3.  Current Challenges for IDO2 as Target in Cancer Immunotherapy.

Authors:  Giada Mondanelli; Martina Mandarano; Maria Laura Belladonna; Chiara Suvieri; Cristina Pelliccia; Guido Bellezza; Angelo Sidoni; Agostinho Carvalho; Ursula Grohmann; Claudia Volpi
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

Review 4.  Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.

Authors:  Xiaotian Song; Qianqian Si; Rui Qi; Weidan Liu; Miao Li; Mengyue Guo; Lin Wei; Zhiyan Yao
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

Review 5.  A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.

Authors:  Francesca Hofer; Gianna Di Sario; Chiara Musiu; Silvia Sartoris; Francesco De Sanctis; Stefano Ugel
Journal:  Cells       Date:  2021-10-09       Impact factor: 6.600

6.  Critical Assessment of a Structure-Based Screening Campaign for IDO1 Inhibitors: Tips and Pitfalls.

Authors:  Andrea Mammoli; Elisa Bianconi; Luana Ruta; Alessandra Riccio; Carlo Bigiotti; Maria Souma; Andrea Carotti; Sofia Rossini; Chiara Suvieri; Maria Teresa Pallotta; Ursula Grohmann; Emidio Camaioni; Antonio Macchiarulo
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

7.  Human Indoleamine 2,3-dioxygenase 1 (IDO1) Expressed in Plant Cells Induces Kynurenine Production.

Authors:  Michele Bellucci; Andrea Pompa; Carine De Marcos Lousa; Eleonora Panfili; Elena Orecchini; Elisa Maricchiolo; Daniele Fraternale; Ciriana Orabona; Francesca De Marchis; Maria Teresa Pallotta
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

8.  Class IA PI3Ks regulate subcellular and functional dynamics of IDO1.

Authors:  Alberta Iacono; Andrea Pompa; Francesca De Marchis; Eleonora Panfili; Francesco A Greco; Alice Coletti; Ciriana Orabona; Claudia Volpi; Maria L Belladonna; Giada Mondanelli; Elisa Albini; Carmine Vacca; Marco Gargaro; Francesca Fallarino; Roberta Bianchi; Carine De Marcos Lousa; Emilia Mc Mazza; Silvio Bicciato; Elisa Proietti; Francesca Milano; Maria P Martelli; Ioana M Iamandii; Mariona Graupera Garcia-Mila; Judith Llena Sopena; Phillip Hawkins; Sabine Suire; Klaus Okkenhaug; Anne-Katrien Stark; Fabio Grassi; Michele Bellucci; Paolo Puccetti; Laura Santambrogio; Antonio Macchiarulo; Ursula Grohmann; Maria T Pallotta
Journal:  EMBO Rep       Date:  2020-11-07       Impact factor: 9.071

9.  The [1,2,4]Triazolo[4,3-a]pyridine as a New Player in the Field of IDO1 Catalytic Holo-Inhibitors.

Authors:  Silvia Fallarini; Irene P Bhela; Silvio Aprile; Enza Torre; Alice Ranza; Elena Orecchini; Eleonora Panfili; Maria T Pallotta; Alberto Massarotti; Marta Serafini; Tracey Pirali
Journal:  ChemMedChem       Date:  2021-08-27       Impact factor: 3.540

Review 10.  One Key and Multiple Locks: Substrate Binding in Structures of Tryptophan Dioxygenases and Hydroxylases.

Authors:  Andrea Mammoli; Alessandra Riccio; Elisa Bianconi; Alice Coletti; Emidio Camaioni; Antonio Macchiarulo
Journal:  ChemMedChem       Date:  2021-07-16       Impact factor: 3.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.